Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment

Patients with aggressive breast cancer (BC) subtypes usually don’t have favorable prognosis despite the improvement in treatment modalities. These cancers still remain a major cause of morbidity and mortality in females. This has fostered a major effort to discover actionable molecular targets to tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Siraj, Abdul Khalid, Pratheeshkumar, Poyil, Parvathareddy, Sandeep Kumar, Divya, Sasidharan Padmaja, Al-Dayel, Fouad, Tulbah, Asma, Ajarim, Dahish, Al-Kuraya, Khawla S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324669/
https://www.ncbi.nlm.nih.gov/pubmed/30647872
http://dx.doi.org/10.18632/oncotarget.26470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324669/
https://www.ncbi.nlm.nih.gov/pubmed/30647872
http://dx.doi.org/10.18632/oncotarget.26470

Ejemplares similares